

animal model studies, as well as in clinical and therapeutic situations, and in the formation of monoclonal antibodies.

Roles of NIEHS

1. Provide design and specifications of synthesizing the opioid dipeptide and assist in beta testing both the labeled and unlabeled ligands, and monoclonal antibodies.
2. Work cooperatively with the company(s) to determine the market potential for these opioidmimetic peptides.

Roles of the CRADA Partner

1. Provide expertise in application and commercial-oriented production of large quantities of opioid peptides.
2. Provide knowledge on the formation, purification, and stabilization of radioactive substances.
3. Provide the expertise for the production of high affinity, high specific monoclonal antibodies.
4. Develop a plan for the production, testing and commercialization of the dipeptide, radiolabeled compounds and monoclonal antibodies.

Selection criteria for choosing the CRADA partner(s) will include, but will not be limited to the following:

1. Experience in peptide synthesis.
2. Capability to produce stable radiolabeled peptides with high specific activity.
3. Ability to develop, implement and manage the product commercialization so as to ensure the dissemination of the substances of research or health care services.
4. Capacity to test labeled peptides and monoclonal antibodies.

Dated: March 13, 1996.

Barbara M. McGarey,

Deputy Director, Office of Technology Transfer.

[FR Doc. 96-7015 Filed 3-21-96; 8:45 am]

BILLING CODE 4140-01-M

National Heart, Lung, and Blood Institute; Notice of Closed Meetings

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following Heart, Lung, and Blood Special Emphasis Panel (SEP) meetings:

Name of SEP: Family Heart Study.

Date: April 8-9, 1996.

Time: 7:30 p.m.

Place: Holiday Inn, Bethesda, Maryland.

Contact Person: Anthony M. Coelho, Jr., Ph.D., Rockledge II, Room 7182,

6701 Rockledge Drive, Bethesda, Maryland 20892-7924, (301) 435-0277.

Purpose/Agenda: To review and evaluate grant applications.

This notice is being published less than fifteen days prior to this meeting due to the urgent need to meet limitations imposed by the grant review cycle.

Name of SEP: The Etiology of Excess Cardiovascular Disease in Diabetes Mellitus.

Date: April 15-16, 1996.

Time: 8:00 a.m.

Place: Ramada Inn, Bethesda, Maryland.

Contact Person: S. Charles Selden, Ph.D., Rockledge II, Room 7196, 6701 Rockledge Drive, Bethesda, Maryland 20892-7924, (301) 435-0288.

Purpose/Agenda: To review and evaluate grant applications.

These meetings will be closed in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5, U.S.C. Applications and/or proposals and the discussions could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications and/or proposals, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

(Catalog of Federal Domestic Assistance Programs Nos. 93.837, Heart and Vascular Diseases Research; 93.838, Lung Diseases Research; and 93.839, Blood Diseases and Resources Research, National Institutes of Health)

Dated: March 19, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-7008 Filed 3-21-96; 8:45 am]

BILLING CODE 4140-01-M

National Institute of General Medical Sciences; Notice of Closed Meeting

Pursuant to Section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting:

Purpose: To review grant applications.

Committee Name: National Institute of General Medical Sciences Special Emphasis Panel—Anesthesiology.

Date: March 19, 1996.

Time: 9 a.m.-11 a.m. (Teleconference).

Place: 45 Center Drive, Conference Room 1AS-13, Bethesda, Maryland 20892-6200.

Contact Person: Dr. Arthur L. Zachary, Scientific Review Administrator, NIGMS, 45 Center Drive, Room 1AS-13, Bethesda, MD 20892-6200.

This meeting will be closed in accordance with the provisions set forth in secs.

552b(c)(4) and 552b(c)(6), Title 5, U.S.C. The discussions of these applications could reveal confidential trade secrets or commercial property such as patentable material and personal information concerning individuals associated with the applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

This notice is being published less than fifteen days prior to the above meeting due to the partial shutdown of the Federal Government and the urgent need to meet timing limitations imposed by the review and funding cycle.

(Catalog of Federal Domestic Assistance Program Nos. 93.821, Biophysics and Physiological Sciences; 93.895, Pharmacological Sciences; 93.862, Genetics Research; 93.863, Cellular and Molecular Basis of Disease Research; 93.880, Minority Access Research Careers [MARC]; and 93.375, Minority Biomedical Research Support [MBRS])

Dated: March 18, 1996.

Susan K. Feldman,

Committee Management Officer, NIH.

[FR Doc. 96-7006 Filed 3-21-96; 8:45 am]

BILLING CODE 4140-01-M

National Institute of Allergy and Infectious Diseases; Notice of Meeting: AIDS Research Advisory Committee, NIAID

Pursuant to Public Law 92-463, notice is hereby given of the meeting of the AIDS Research Advisory Committee, National Institute of Allergy and Infectious Diseases, on May 21, 1996 in Conference Room E1 & 2 of the Natcher Conference Center (Building 45) at the National Institutes of Health, 9000 Rockville Pike, Bethesda, Maryland.

The entire meeting will be open to the public from 8:30 a.m., until adjournment. The AIDS Research Advisory Committee (ARAC) advises and makes recommendations to the Director, National Institute of Allergy and Infectious Diseases, on all aspects of research on HIV and AIDS related to the mission of the Division of AIDS (DAIDS).

The Committee will provide advice on scientific priorities, policy, and program balance at the Division level. The Committee will review the progress and productivity of ongoing efforts, and identify critical gaps/obstacles to progress. Attendance by the public will be limited to space available.

Ms. Rona L. Siskind, Executive Secretary, AIDS Research Advisory Committee, DAIDS, NIAID, NIH, Solar Building, Room 2A21, telephone 301-496-0545, will provide a summary of the meeting and a roster of committee members upon request. Individuals who plan to attend and need special